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Abstract
Background: The diagnosis of Pulmonary Embolism (PE) in the emergency department (ED) is crucial. As emergency
physicians fear missing this potential life-threatening condition, PE tends to be over-investigated, exposing patients to
unnecessary risks and uncertain benefit in terms of outcome. The Pulmonary Embolism Rule-out Criteria (PERC) is an
eight-item block of clinical criteria that can identify patients who can safely be discharged from the ED without further
investigation for PE. The endorsement of this rule could markedly reduce the number of irradiative imaging studies, ED
length of stay, and rate of adverse events resulting from both diagnostic and therapeutic interventions. Several
retrospective and prospective studies have shown the safety and benefits of the PERC rule for PE diagnosis in low-risk
patients, but the validity of this rule is still controversial. We hypothesize that in European patients with a low gestalt
clinical probability and who are PERC-negative, PE can be safely ruled out and the patient discharged without further
testing.
Methods/Design: This is a controlled, cluster randomized trial, in 15 centers in France. Each center will be randomized
for the sequence of intervention periods: a 6-month intervention period (PERC-based strategy) followed by a 6-month
control period (usual care), or in reverse order, with 2 months of “wash-out” between the 2 periods. Adult patients
presenting to the ED with a suspicion of PE and a low pre test probability estimated by clinical gestalt will be eligible.
The primary outcome is the percentage of failure resulting from the diagnostic strategy, defined as diagnosed venous
thromboembolic events at 3-month follow-up, among patients for whom PE has been initially ruled out.
Discussion: The PERC rule has the potential to decrease the number of irradiative imaging studies in the ED, and is
reported to be safe. However, no randomized study has ever validated the safety of PERC. Furthermore, some studies
have challenged the safety of a PERC-based strategy to rule-out PE, especially in Europe where the prevalence of PE
diagnosed in the ED is high. The PROPER study should provide high-quality evidence to settle this issue. If it confirms
the safety of the PERC rule, physicians will be able to reduce the number of investigations, associated subsequent
adverse events, costs, and ED length of stay for patients with a low clinical probability of PE.
Trial registration: NCT02375919.
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Background
Pulmonary embolism in the emergency department
The incidence of pulmonary embolism (PE) in France
and Europe has been estimated to 0.6–0.9 per 1000 per-
sons per year [1, 2]. PE is a potentially lethal diagnosis
[3], and its diagnosis in the Emergency Department (ED)
is challenging [4].
The fear of missing this diagnosis and the poor specifi-
city of its clinical presentation has led physicians to sus-
pect PE in patients who present with a broad variety of
symptoms such as dyspnea, chest pain, syncope, and
hypotension. These patients account for more than 10
millions ED visits a year in the United States. For the
last decade, the strategy for PE diagnosis has been well-
defined (Fig. 1). The usual work-up for PE diagnosis first
includes an assessment of the clinical probability of PE,
using a structured score (the Revised Geneva Score
(RGS) or Wells’ score [5, 6]), or an unstructured estima-
tion of the clinical probability (referred to as the clin-
ician “gestalt” [7–9]). In patients with low clinical
probability to moderate clinical probability, sensitive D-
dimer testing should be followed if positive by a Com-
puted Tomography Pulmonary Angiogram (CTPA) in
the absence of contra-indication. Patients with a high
clinical probability should undergo CTPA without the
need for preliminary testing. This diagnostic strategy is
recommended by European guidelines [10], national ex-
pert recommendations [11] and local policies. It has
been validated and is safe to exclude PE in outpatients
visiting the ED [12]. However, due to its low specificity
(40–60 %) [9, 13], D-dimer testing may lead to more
than 50 % of false positives and subsequent CTPA [9].
Furthermore, the wide availability of D-dimer testing,
combined with the fear of missing PE, has led to lower-
ing the testing threshold for suspicion of PE; hence the
decrease in the prevalence of confirmed PE from 30 %
to below 10 % in the United States [14–17].
Subsequently, there has been a marked rise (up to 15-
fold) in the utilization of CTPA in the last 15 years [18]
and in the incidence of diagnosed PE [19]. However, this
greater incidence of PE was not followed by a decrease
in the mortality rate from PE, but rather a global de-
crease in PE fatality [19, 20]: the prognosis of a patient
with a PE improves, but the overall number of deaths
from PE do not change. This suggests that PE tends to
be “overdiagnosed”: small PEs are more frequently diag-
nosed, with no clear benefit in terms of outcomes. This
increased exposure to CTPA may be a source of un-
necessary risks, such as contrast-induced nephropathy
and allergic reactions, adverse events after anticoagula-
tion treatment or the delayed occurrence of radiation-
induced cancer [21–23].
The PERC rule
Assessing the benefit risk ratio for PE investigation, it
has been calculated (using the Pausker and Kassirer
method [24]) that if the pre test probability (PTP) is
below 1.8 %, patients should not undergo D-dimer test-
ing because a positive result would mandate a CTPA,
which would have a negative benefit risk ratio [15]. To
reduce the rate of unnecessary testings for PE caused by
overuse of D-dimer, in 2004 Kline et al. developed a
block rule of 8 binary variables (PERC rule): age <
50 years, pulse < 100 bpm, arterial oxygen saturation
(SpO2) > 94 %, no unilateral leg swelling, no hemoptysis,
no recent trauma or surgery, no prior PE or deep venous
thrombosis (DVT) and no exogenous estrogen use [15]
– PERC-negative patients are defined as fulfilling these 8
criteria. Kline et al. applied this rule in their princeps
study to low-clinical-probability patients, defined by a
probability of less than 15 % by empirical clinical gestalt
[15, 16]. They reported that the prevalence of PE for
PERC-negative patients was 1.4 % (95 % confidence
interval (CI) 0.5–3 %). This low rate suggests that
PERC-negative patients could be safely discharged after
clinical examination without further testing. Moreover,
the rate of 1.4 % is below the reported upper limit of
false-negative rates after pulmonary angiogram or CTPA
(3 %) [12, 25, 26], which advocates for a safe alternative
to further testing.
Following this princeps study, several other studies
assessed the safety of a PERC-based policy to exclude PE
in low-risk emergency patients with a PERC-negative
rule. Two meta-analyses [17, 27] confirmed the benefits
and safety of the PERC rule, with a rate of PE after
follow-up lower than 1 % in PERC-negative patients.
They included 10 prospective and 3 retrospective stud-
ies, i.e. non-interventional studies only, accounting for a
total of 14,844 ED patients with a suspicion of PE. Three
Fig. 1 Standard strategy for the diagnosis of pulmonary embolism
(PE) in the Emergency Department (ED). ED, Emergency Department;
PE, pulmonary embolism; RGS, Revised Geneva Score
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of the 13 studies were conducted in Europe (France,
Belgium and Switzerland) [28–30]. In the first 2 European
studies [28, 29] the prevalence of PE amongst PERC-
negative patients was 5.4 % and 6.7 %, respectively
(95 % CI 3–10 %). Their authors argued that the
higher prevalence of PE in Europe (>20 % [17]) than
in the United States (<10 % [17]) was the main rea-
son for this lower negative predictive value, and that
this rule should not be applied in high-prevalence
populations. Based on the poor performance of the
PERC rule, European physicians have been reluctant
to apply it for excluding PE in low-risk patients. However,
these two studies had several methodological bias: both
studies were retrospective and did not collect PERC items
prospectively. Moreover, the studied samples were not
solely patients with a low gestalt clinical probability: they
included unselected patients with suspected PE in the ED,
with low PTP to high PTP. Although authors from one
study ran a sensitivity analysis focusing on patients with
low PTP, this was assessed using the Revised Geneva
Score (RGS) that is based on redundant items with those
of the PERC rule. These specific limits, coupled with the
greater prevalence in the European studies, might explain
the greater rate of false negatives. A few years later,
Penaloza et al. reported that the PERC rule was safe even
in Europe, when combined with a low clinical probability
assessed by physician’s gestalt [30], with no venous
thromboembolic (VTE) event after 3-month follow-
up. Accordingly, in a recent multicenter retrospective
study, we also observed a very low prevalence of PE
(0.5 % (95 % CI 0.1–1.1 %)) amongst low-risk, PERC-
negative ED patients [31].
Of note, all of the previously cited studies were either
prospective or retrospective, but no randomized study
has yet compared the benefit risk ratio of a PERC-based
strategy versus the standard diagnostic strategy (Fig. 2)
on occurrence of undiagnosed PE in low-risk patients.
Methods
The PROPER trial is a cluster randomized trial in
France. The primary objective of this study is to assess
the non-inferiority of a PERC-based diagnostic strategy
for PE low-risk emergency patients, compared to the
standard strategy of D-dimer testing, on the occur-
rence of undiagnosed VTE events. Our institutional
review board authorized the study with the need for a
signed informed consent from the patient (Comité de
protection des personnes, Paris Ile de France 6,
A00215-44).
Experimental plan
Each center will be randomized for the period: a 6-
month intervention period followed by a 6-month con-
trol period, or a 6-month control period followed by a 6-
month intervention period. The randomization will be
prepared by URC-Est using permutation blocks (SAS
9.3, SAS Inc., Cary, NC, USA) before the first site initi-
ation visit. The design, conduct and reporting of this
study will follow the Consolidated Standards of Report-
ing Trials (CONSORT) statement extended to cluster
randomized trials [32]. The two groups will have a dif-
ferent work-up for the diagnosis of PE in the ED as
follows:
 Control group: standard strategy: conventional PE
work-up. Every low-risk patient will undergo sensi-
tive D-dimer testing, with subsequent CTPA if posi-
tive. In case of negative D-dimer, PE will be
considered as excluded (Fig. 2a).
 Intervention group (PERC-based strategy): PE work-
up based on the use of the PERC rule. If all PERC
criteria are negative, no further testing for PE will be
recommended. If at least one criterion is positive,
then the patient will undergo sensitive D-dimer test-
ing, with subsequent CTPA if positive. In case of
negative D-dimer result, PE will be considered as ex-
cluded (Fig. 2b).
It has been recently reported that the cut-off for posi-
tive D-dimer should be changed for patients aged >
50 years to age × 10 ng/ml [33]. This strategy has been
validated in a large multicenter international trial [34].
This strategy is actually endorsed by our centers. The
strategy for defining “positive D-dimer” (age × 10 ng/ml
for patients older than 50 years) will be stated before the
start of the study in each center and not changed during
Fig. 2 Work-up for diagnosis of pulmonary embolism (PE). a Control group. b Intervention group. CTPA, Computed Tomography Pulmonary
Angiogram; PE, pulmonary embolism; PERC, Pulmonary Embolism Rule-out Criteria
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the whole study period. Of note, this change will only
concern patients aged 50 years or greater, i.e. with a
PERC > 0. As this will not affect PERC-negative patients,
there will be no interference with our objectives.
Selection of participants
All patients with chest pain or dyspnea who attend one
of the participating centers will be screened for eligibility
by ED physicians and research assistants. If the treating
ED physician or local investigator considers that the pa-
tient has a sufficient clinical suspicion of PE and that he
needs a formal work-up for this diagnosis, and that this
suspicion is low enough to discard this suspicion in case
of negative D-dimer (i.e. estimated as less than 15 %),
then the patient will be eligible. When a patient is eli-
gible, his written informed consent will be obtained. In
case of inability to consent, the patient will not be in-
cluded in the study. The inclusion criteria are as follows:
 Patients ≥ 18 years presenting to an ED AND
 New onset of, or worsening of shortness of breath
or chest pain AND
 A low clinical probability of PE, estimated by the
clinician gestalt (unstructured empirical probability
of PE) to be lower than 15 %
Exclusion criteria include the presence of any obvious
cause other than a PE of symptoms, an acute severe
presentation (clinical signs of respiratory distress,
hypotension, SpO2 < 90 %, shock), a contraindication to
CTPA (allergy, or estimated creatinine clearance less
than 30 ml/min), pregnancy, concurrent anticoagulation
treatment, current diagnosis of VTE event, inability to
follow-up or to provide informed consent, lack of cover-
age for medical insurance, being a prisoner, and partici-
pation in another intervention trial.
After a patient is screened in the ED and may be in-
cluded, the patient’s emergency physician, the local in-
vestigator or a clinical research technician (CRT) will
inform them of the trial, and obtain signed informed
consent. After a patient is included in the study, the
local investigator, the patient’s emergency physicians, or
the CRT will collect data on their past medical history,
vital signs on admission, PERC, RGS, Wells’ score,
examination in the ED and discharge disposition. This
will be collected on a paper Case Report Form (CRF),
later entered on an electronic CRF (eCRF). Any missing
data will be sought through electronic or paper records
of the patients, under the supervision of the local inves-
tigator of the center.
Trial objectives and outcomes
The primary objective of this study is to assess the non-
inferiority of a PERC-based diagnostic strategy for ED
patients with a low probability of PE based on physi-
cian’s gestalt, compared to the standard strategy of D-
dimer testing, on the prevalence of undiagnosed VTE
events. The secondary objectives are the following:
1) to assess the reduction of unnecessary irradiative
imaging studies and adverse events
2) to assess the reduction in ED length of stay
3) to assess the reduction of onset of anticoagulation
regimen and associated adverse events
4) to assess the reduction of hospital admission
following the ED visit, hospital readmission, and
mortality at 3 months.
The primary outcome is the percentage of diagnostic
strategy failure, defined as diagnosed VTE at 3-month
follow-up, among patients for whom PE has been ini-
tially ruled-out. Exclusion of PE in the ED is made based
upon a negative D-dimer result or a negative CTPA in
both groups, or a negative PERC in the intervention
group.
Follow-up will be made by telephone interview of the
patient or his general practitioner, and review of any out-
patient consultation or hospital visit at 3 months
(13 weeks) by a CRT. The time frame of the 3-month
follow-up period could be subject to minor adjustments,
but should occur between day 84 and day 98. Follow-up
visit or interview will seek the occurrence of VTE events
(DVT documented with ultrasonography of the lower
limbs or venous computed tomography (CT), or PE doc-
umented with positive CTPA or high probability ventila-
tion/perfusion (V/Q) lung scan), death, return visit to
the ED, and hospitalization. All medical records pertain-
ing to the patient within this timeframe will be sought
and analyzed by the local investigator, looking for re-
ports of VTE events, or adverse events from CTPA or
anticoagulation. In case of death, report of a VTE, or
major cardiovascular event, the file will be analyzed by a
committee of three independent experts. This method of
adjudication has been described and validated in all
major previous PE diagnostic studies [35, 36].
The primary criterion of a VTE event will be based on
an objective diagnosis of DVT on Doppler ultrasonog-
raphy, an intraluminal defect on CTPA, or a V/Q lung
scan with a reported high probability. To confirm the
occurrence of the primary endpoint, all files with evi-
dence of a thromboembolic event collected by the local
investigator of each center will be independently
reviewed by an adjudication committee of three experts,
blinded one to the other, and blinded to the study group.
The adjudication committee will also review cases of
death with no evidence of VTE event and will adjudicate
whether or not the death is likely related to a PE. A sud-
den death in the absence of other obvious cause will be
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adjudicated as related to a PE. This committee will in-
clude three members, independent from the trial, with
expertise in the field of PE, and will meet the recom-
mendations of Dechartres et al. [37].
The result of adjudication regarding the primary end-
point, and other secondary endpoints at follow-up will
be entered on the eCRF by a CRT or the local
investigator.
Statistical analysis
No interim analysis is planned.
Baseline characteristics of patients will be described
according to group of intervention. Continuous variables
will be summarized using descriptive statistics, i.e. num-
ber of subjects, mean, median, standard deviation (SD),
interquartile range, minimum and maximum. Qualitative
variables will be summarized by frequency and percent-
age. Since this is a non-inferiority study, analysis of the
principal criterion will be performed on a per-protocol
population. Secondary analysis will be performed based
on the intention-to-treat (ITT) principle. VTE events
will be defined by: DVT (assessed by proximal compres-
sion ultrasonography) or PE (a CTPA or angiography
showing intraluminal defect, or a V/Q lung scan showing
a high-probability pattern). The decision rule will be
based on the upper bound of the 90 % 2-sided CI of the
difference of percentage of VTE events between groups.
If the upper bound of the CI is above the 1.5 % of differ-
ence, the non-inferiority hypothesis of the intervention
group will be rejected. The Dunnett and Gent chi square
test will also be performed. Secondary analysis will be
performed on the ITT population. Considering cluster
randomization, confirmatory analysis will be performed
using a generalized estimating equation (GEE) assuming
an exchangeable correlation matrix structure and con-
sidering clustering at the site level. Secondary criteria
will be compared under superiority hypothesis and on
the ITT population. Descriptive analysis will be per-
formed. Superiority approach will be used to compare
secondary evaluation criteria between groups. The ED
length stay and the mean proportion of hospital admis-
sions following the ED visit will be compared using a
mixed model, considering “center” as random effect. Un-
necessary irradiative imaging, adverse events and deaths
at 3 months will be compared using GEE assuming an
exchangeable correlation matrix structure and consider-
ing clustering at site level. All superiority tests will be
performed at 5 %. Pre-specified secondary analysis will
include comparison of gestalt, Wells’ score and RGS,
and performances of the PERC35 score for patients aged
under 35 years [38]. Missing data will not be replaced
except for the principal criteria for the secondary ITT
analysis. Missing value will be considered as an event
whatever the group randomized.
According to recent large European cohorts, we estimate
that the primary endpoint rate in our control group will be
1.5 % [35, 36, 39]. To be regarded as non-inferior, the
maximal difference in proportions between 2 groups
(Delta) should not exceed 1.5 % – an absolute primary
event rate of 3 % in the intervention group. This failure
rate corresponds to the upper bound of the observed rate
after a negative CPTA and is a widely accepted criterion
for the validation of diagnostic strategies for PE [40]. This
rate is in line with previous landmark studies that comprise
the basis of our current understanding.
Sample size under non-inferiority hypothesis
To assess non-inferiority of the “PERC strategy,” with 1-
sided alpha = 5 %, beta = 20 %, N1 = 1624 subjects are
needed (East 6, Cytel, Cambridge, MA, USA). A cluster
is a 6 months period for 1 site. Under the assumption of
an intraclass correlation coefficient of 0.002, an intra-
period correlation of 0.001 and a mean cluster size for
one period of 60 patients, the cluster design effect would
be of D = 1.118. Considering 5 % of non-evaluable sub-
jects, with 15 sites involved in the trial, which corre-
sponds to 30 clusters, 61 subjects per site per period are
required and will lead to a total of 1920 patients.
Discussion
PE is a diagnosis that affects nearly 200,000 patients
each year in France. The multiplication of diagnostic
studies led to a rise in PE diagnosis, associated with a
concurrent rise in the diagnosis of minor PE, and no
subsequent decrease in mortality [18–20].
According to many retrospective studies including
ours, the rate of PERC-negative patients amongst pa-
tients with a low clinical probability of PE ranges
from 15–30 % [15, 28, 30, 31]. If the PERC rule was
used in place of a conventional D-dimer-based diag-
nostic strategy, more than 10 % of CTPAs could be
avoided [31, 41].
Such reduction in imaging studies would be beneficial
for patients. The main medical harms that can be caused
by unnecessary testing for PE include adverse events
from CTPA: increased risk of delayed solid tumor occur-
rence from irradiative imaging, and iatrogenic complica-
tions of anticoagulation for positively tested patients
(either false positives or true positives for small PEs).
Moreover, the benefits of diagnosing PE in low-risk
patients are unclear. Mortality for patients with suspi-
cion of PE seems very low: Kline reported that among
more than 8000 patients tested for PE in the ED, only
13 patients (0.2 %) died because of PE (written
communication).
In 2011, Newman and Schriger extrapolated the risks
and benefit of D-dimer testing among a sample of
10,000 PERC-negative patients [41]. This supplemental
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testing could lead to the diagnosis of 30 PE that would
have been missed (credible interval 6–60). However, fur-
ther testing in these 10,000 PERC-negative patients may
cause 73 adverse events (credible interval 14–140)
among which 36 fatal events (credible interval 4–69).
The causes of adverse events were acute renal failure
from contrast-induced nephropathy (50 per 10,000 pa-
tients), severe hemorrhage due to anticoagulation treat-
ment (17 per 10,000 patients), and cancer resulting from
radiation (5 per 10,000 patients).
Besides the estimated unfavorable medical benefit risk
ratio for the patient, further testing has clear downsides:
a prolonged stay in the ED, contributing to overcrowd-
ing [42, 43], overall worse short-term outcomes [44],
and increased costs. In a retrospective study, median
CTPA time in the ED has been reported to be 160 mi-
nutes, accounting for more than half of total ED [41].
ED length of stay could be greatly reduced if PERC was
endorsed: nearly a quarter of patients with a low PTP
could be discharged after just a physical examination,
without the need for time-consuming biological and im-
aging studies.
Finally, avoiding any supplemental investigations for
PERC-negative patients may also reduce the costs of ED
visits, which would be of great benefit in the context of
increasingly resource-stretched healthcare services.
Thus, if the PERC-based strategy is shown to be non-
inferior to the standard strategy, it will safely and sub-
stantially reduce the volume of D-dimer and CTPA test-
ing and, therefore, irradiation, adverse events, length of
ED stay and overcrowding.
The risk for a patient recruited in the experimental
group is that of a false negative PERC score, whilst the
patient actually has a PE. This risk has been reported to
be below 1 % in previously cited meta-analyses. Further-
more, potential false-negative patients would belong to
the group at lower PE risk, with an estimated 30 days
mortality below 1 % [45–47] – on top of the overall
mortality rate estimated in the conventional group
(0.2 %), the overall extrapolated added risk would be
below 1/10,000 at 30 days in the experimental group.
The PROPER study is a large international cluster
randomized controlled trial that aims to validate the
safety of the PERC rule to exclude PE in emergency
patients with a low clinical probability. This trial is
the first to prospectively implement and evaluate
PERC in a controlled fashion to validate what previ-
ous meta-analyses have reported, and may end the
controversy in this European high-prevalence popula-




CONSORT: Consolidated Standards of Reporting Trials; CRF: Case Report
Form; CRT: clinical research technician; CT: computed tomography;
CTPA: Computed Tomography Pulmonary Angiogram; DVT: deep venous
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